SCHEMBL884965

SCHEMBL884965

c1cncc(Nc2ccc(CC(c3cccnc3)c3cccnc3)cc2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
CFTR P13569 2/20 0.47
GOPC Q9HD26 2/20 0.47
AKT1 P31749 1/20 0.46
KCNA5 P22460 3/20 0.46
KCNH2 Q12809 2/20 0.46
KDM4E B2RXH2 1/20 0.45
RAB9A P51151 2/20 0.44
SLC6A2 P23975 2/20 0.44
SLC6A4 P31645 2/20 0.44
SLC6A3 Q01959 2/20 0.44
EPHX2 P34913 1/20 0.42
RAD52 P43351 1/20 0.41
KMT2A Q03164 1/20 0.41
LTA4H P09960 1/20 0.41
KDR P35968 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL884770 0.85 CYP1A2 (0.54) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL884888 0.82 CYP1A2 (0.54) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL14148585 0.78 ALDH1A1 (0.54) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4197953 0.78 KCNA5 (0.50) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL884669 0.77 KCNA5 (0.51) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL884862 0.77 KCNA5 (0.57) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL29845262 0.76 KMT2A (0.61) CFTRGOPCRAB9ASLC6A2RAD52
SCHEMBL4591751 0.76 KMT2A (0.61) CFTRGOPCRAB9ASLC6A2RAD52
SCHEMBL884742 0.75 CYP1A2 (0.46) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL884975 0.75 KCNA5 (0.52) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US claimed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP claimed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO claimed
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233897-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 CYP1A2 2371/4885CYP3A4 1526/4885CYP2D6 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.